Pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs) play key roles in initiating innate and adaptive immune responses. Based mainly on animal studies there is growing evidence to suggest that TLRs are involved in the development of chemotherapy-induced mucositis and in the propagation of graft versus host reactions as well as graft versus tumor effects in allogeneic hematopoietic stem cell transplantation (HSCT). In this review we discuss these findings along with the emerging, although still preliminary, clinical evidence, that points to a role of PRRs in determining the outcome of HSCT and new therapeutic perspectives that may be related to this development.
INTRODUCTION
Although overall survival after allogeneic stem cell transplantation (HSCT) has improved significantly through the last decade, HSCT still carries a considerable risk of acute toxicities, significant late effects and relapse of malignancy. 1 These risks are to a high degree influenced by disturbances in both innate and adaptive defense mechanisms that may lead to infections, alloreactivity or insufficient immunologic control of the malignant disease.
Toll-like receptors (TLRs) are germline-encoded membrane bound recognition receptors that play key roles in host immune responses. TLRs are expressed on the plasma membrane and in organelles such as endosomes and lysosomes of innate immune cells, but can also be found in other cells such as epithelial cells, endothelial cells and cancer cells. 2 TLRs recognize conserved microbiota associated molecular patterns (MAMPS) that are specific to invading microorganisms, including secretory products, DNA and RNA from bacteria, virus and fungi. Ligand binding by TLRs activates innate immune responses including dendritic cells and cytokine production and eventually leads to an adaptive immune response. In conditions, such as HSCT, where the adaptive immune homeostasis is disturbed, these key players of innate immunity may take a more central protective role, but they may also cause activation of potentially harmful, dysregulated immune responses. 3, 4 Far the most knowledge on the role of TLRs is based on studies in rodents, while clinical studies are sparse. In this review we will discuss how far we have come in our understanding of the role of TLRs with a main focus on the clinical setting of HSCT, addressing interactions between innate immune mechanisms initiated in relation to mucositis and adaptive immune reactivity towards host cells and cancer cells.
TLR AND MUCOSITIS
Mucositis is a major challenge in HSCT, occurring in 60-85% of patients treated with a myeloablative conditioning regimen before autologous or allogeneic HSCT. 5, 6 Studies suggest that 30-50% of all primary bloodstream infections in cancer patients can be related to alimentary tract mucositis. 7, 8 The development of mucositis is initiated immediately after the toxic insult, where DNA damage and the formation of reactive oxygen species lead to activation of NFkB and subsequently activation of a series of processes causing cellular damage and the release of damage associated molecular patterns (DAMPs), such as ATP, uric acid crystals and double stranded DNA 5,9 ( Figure 1 ). These endogenous molecules may be sensed by pattern recognition receptors (PRR), such as cytoplasmatic nucleotidebinding oligomerization domain receptors (NOD-like receptors (NLR)), causing the release of inflammatory cytokines, including the bioactive form of IL-1beta and IL-18. 10 Similarly, endogenous molecules produced as a result of cell death and injury may also be recognized by TLRs thereby triggering inflammation. These include degradation products of extracellular matrix, heat-shock proteins and high mobility group box 1 (HMGB1), that act as ligands for surface TLRs, such as TLR 2, 4 and 6. In addition, HMGB1 and self DNA may gain access to endosomal TLRs (TLR7, TLR9) further propagating inflammation. 2, 11 A study addressing HMGB1 single nucleotide polymorphisms (SNPs) did not provide evidence of an impact on survival in HSCT, but further investigation of these TLR-sensed endogenous molecules is needed. 12 Although resident microbiota, in the alimentary tract, do not play a defined role in the initiation of mucositis according to a widely accepted model of mucositis, 13 there is circumstantial evidence suggesting a role for TLR mediated effects of dysbiosis in the pathogenesis of mucositis. Indeed, human as well as animal studies show significant alterations in the intestinal flora following both myeloablative and conventional chemotherapy, and these changes coincide with mucositis and increased systemic inflammation. 4, [14] [15] [16] [17] In a study of 31 patients undergoing HSCT Holler et al.
14 reported a shift towards predominace of enterococci in the intestinal microflora after HSCT. This was most pronounced under antibiotic prophylaxis and treatment of neutropenic infections, with predominance of Enterococcus faecium and Enterococcus faecalis.
14 Using next generation sequencing, Montessier et al. 18 studied changes in the microbiome in eight patients with non-Hodgkin's lymphoma one week after HSCT conditioning. These authors reported a reduction in Faecalibacterium accompanied by an increase in Escherichia, thereby inducing a shift in the microflora towards a phenotype that has been associated with anti-inflammatory properties. 18 These findings are also important because bacterial microbiota have been found to influence epithelial growth, formation of tight junctions, permeability and mucus production as well as the expression of inflammatory and anti-inflammatory cytokines and immune effector molecules (Figure 1) . 4, 19, 20 Despite this, any specific bacterial strain that may induce or aggravate chemotherapy induced mucositis has not yet been conclusively demonstrated in humans.
During the later ulcerative phase of mucositis, breaks in the mucosa may serve as portals of entry for microorganisms leading to bacteremia. In addition, cell-wall products from colonizing bacteria may penetrate into the submucosa and activate cytokine production by infiltrating mononuclear cells through engagement of TLRs 1 and 2. 21, 22 Of those TLR2 is involved in recognition of a wide range of PAMPs derived from bacteria, fungi, parasites and viruses, 23 while TLR-4 responds to bacterial lipopolysaccharide, a component of the outer membrane of gram negative bacteria that may cause septic shock. 3, 24 TLR5 is highly expressed on dendritic cells in the lamina propria of the small intestine and recognizes components of bacterial flagella, promoting the Th17 phenotype, which may be of potential importance in the pathogenesis of acute graft versus host disease (aGvHD). 25 This two-cycle engagement of PRRs-with a primary engagement of TLRs by DAMPs and a secondary step with recognition of PAMPs, is reflected into a two-peaked inflammatory response, with a primary wave of inflammatory markers during the pretransplant conditioning phase, and a secondary wave of inflammation peaking during the phase of clinical mucositis and severe neutropenia. 26 The height of inflammation seen during both phases has been found predictive of overall mortality in HSCT, 27, 28 and the perspective to modulate this inflammatory response by TLR antagonists, that are currently under development, is of potential great interest.
1 TLR-9 antagonists have been shown to decrease chemotherapy induced-induced gastrointestinal mucositis, while other studies suggested a role for modulation of TLR-2 signaling in experimental animals. 29, 30 Thus, pharmacologic modulation of TLR mediated host-microbiota interactions may prove fruitful in the search for new strategies to limit treatment related mucositis and potentially harmful systemic inflammation. , which impairs enterocyte functions, such as proliferation, tight junction formation and mucus production. 64 In combination with damage to the intestinal epithelial cells induced by the conditioning regimen, loss of epithelial integrity leads to translocation of bacteria, release of pathogen associated molecular patterns (PAMPs) and endogenous damage associated molecular patterns (DAMPs), which activate host cells, including epithelial cells and antigen presenting dendritic cells (DC) through pattern recognition receptors (c), such as extracellular or intracellular TLRs. Both enterocytes and APC release a variety of inflammatory cytokines leading to the activation of donor CD8 + cytotoxic T-cells (d) and naïve CD4 + T helper cells (e). The activated CD8 + T-cells induce cytotoxic tissue damage directly, while CD4 + helper T-cells inducing proliferation of proinflammatory Th1 and Th17 T-cells over anti-inflammatory regulatory T-cells, further propagate the proinflammatory response and aGvHD (f). T-cells expressing TLRs may also be directly influenced by TLR ligands. 65 Modified from Heidegger et al. 40 and Valentini et al. 65 A full color version of this figure is available at the Bone Marrow Transplantation journal online.
TLR AND ACUTE aGvHD According to a current and widely accepted model, toxic damage of the intestinal mucosal surfaces plays a central role in the development of aGvHD. 31 This hypothesis is mainly based on animal studies and suggests that PAMPs, translocating through leaky epithelial barriers, as well as DAMPs are bound by PRRs such as TLRs, causing release of inflammatory mediators that may propagate aGvHD by activating alloreactive donor T-cells (Figure 1 ). In line with this, prime targets for aGvHD are organs that interact with the surrounding microbiota such as skin, gut, lungs and liver. Early studies indicated that transplants in germ free mice and in patients undergoing antibiotic decontamination led to less severe aGvHD. [32] [33] [34] However later studies showed no clear benefits. 35 More recently it has been suggested that dysbiosis may be a risk factor for aGvHD (Figure 1 ). The importance of the beneficial effects of the normal gut flora is increasingly recognized, and the maintenance of the homeostatic balance between host cells and the intestinal microbiome has come into focus. Jenq et al. 36 found that the risk of aGvHD of the gut in mice and in humans was associated with changes in the microbiome, and that restoring the predominant species of Lactobacillus mediated significant protection against aGvHD in mice. A more recent study demonstrated that reduction in Blautia, a member of Clostridiales, is associated with increased aGvHD related mortality. 37 Holler et al. 14 found that reduction in diversity and a shift towards predominance of enterococci was most pronounced in patients developing intestinal aGvHD. Indirect evidence for a role of dysbiosis in the pathogenesis of aGvHD was also obtained in a recently reported clinical study finding that treatment of neutropenic fever with imipenem-cilastatin and piperacillin-tazobactam, antibiotics in humans is associated with enteral dysbiosis and increased risk of aGvHD, while other antibiotic regimens did not show an association with aGvHD. 38 Although the design of these clinical studies does not allow conclusions regarding causality, they lend support to a role of dysbiosis as a risk factor of aGvHD.
These associations between risk of aGvHD and microbiome patterns may be TLR mediated or they may be mediated through non-TLR mechanisms that act to protect intestinal integrity. In a recent study Mathewson et al. 39 found decreased intestinal levels of the microbiota-derived short-chain fatty acid, butyrate, after HSCT in mice. Administration of butyrate, as well as administration of bacterial strains that are high producers of butyrate, improved intestinal epithelial cell junctional integrity, decreased apoptosis and mitigated aGvHD, suggesting a protective effect of this microbial metabolite on aGvHD target tissues. 39 In addition to non-TLR related pathways, host-microbiome interactions related to aGvHD may also be mediated through TLR interactions. This has been studied most extensively in rodents and recent reviews include that of Heidegger et al. 40 Studies in mice have indicated a role of TLR 4, 5, 7 and 9, but results have been inconsistent, and factors such as differences in location of aGvHD, kinetics and the experimental conditions may have influenced the results obtained in these animal studies. 40 Apart from gene association studies, evidence from human studies on the role of TLRs in aGvHD is sparse, and in some cases contradictory to the findings in mice, as exemplified by TLR5 which has been found upregulated in patients with aGvHD, while in mice apparently mediating reduced aGvHD. [41] [42] [43] [44] These discrepancies may to some degree be related to the fact that around 85% of the genera detected in mouse have not been found in humans. 45 The precise role of TLRs in aGvHD pathogenesis is still controversial and warrants further investigation.
TLR AND THE GRAFT VERSUS TUMOR EFFECTS
Although the role of TLRs and other PRRs in cancer immunotherapy is being investigated, only limited data exist on the role of TLR in the context of HSCT and graft versus tumor effects (GVT). In a recent murine study of the myeloid differentiation response gene (MyD88), that mediates TLR signaling, recipients of MyD88 knock out grafts experienced unabated tumor growth concomitantly with aGvHD. 46 In contrast recipients of MyD88 wildtype grafts showed evidence of GVT responses, suggesting an important role of TLRs on GVT.
Modulation of the allo-response towards a more GVT prone phenotype has been attempted by administrating TLR agonist in murine transplant models. In a human observational study GVT effects after DLI, were associated with TLR activation, including TLR9 activation. 47 This is of interest in relation to other studies showing that treatment with synthetic oligodeoxynucleotides, containing unmethylated cytosine-phosphate-guanosine (CpG) motifs binding TLR9, enhanced GVT effects without aggravating aGvHD. [48] [49] [50] Similar findings were seen after treatment with a specific TLR5 agonist derived from salmonella flagellin. In a retrospective study where plasmacytoid dendritic cells (pDC) were investigated after bone marrow or cord blood transplantation, pDC from cord blood recipients displayed impaired activation in response to stimulation with the TLR9 agonist CpG, possibly explaining the increased infectious rates and lower rates of aGvHD and GVT effects after cord blood transplantation, emphasizing the importance of TLR9 in alloreactivity. 51 
TLR IN CLINICAL ALLOGENEIC HSCT
In the setting of clinical allogeneic HSCT, TLRs have mostly been investigated in the context of SNPs ( Table 1 ). The most extensively studied polymorphisms are the two functional TLR4 SNPs, Asp299Gly and Thr399Ile, which have been investigated in most of the studies published on the subject to date. Initial interest was spurred in a study by Lorenz et al. 52 where a non-significant trend between Asp299Gly and Thr399Ile and lower incidence of aGvHD and higher incidence of gram-negative bacteremia were observed in 237 patients and their HLA-identical sibling donors. Although, the particular findings by Lorenz et al. 52 could not be confirmed in several later studies, [53] [54] [55] interest centered on the association between TLR4 SNPs and diminished response to constituents of microbial cell-walls. In a landmark study designed with a discovery and validation cohort, Bochud et al. 56 identified a TLR4 donor haplotype including the Asp299Gly and Thr399Ile SNPs, which was associated with increased risk of invasive aspergillosis among recipients of unrelated donor allogeneic transplants. These findings were later confirmed in two independent cohorts. 57, 58 Of interest in this connection Camargo et al. 59 found decreased TLR2 but increased TLR4 expression on circulating monocytes in hematologic patients with mucormycosis. The TLR4 Asp299Gly in recipients and donors has also been associated with hemorrhagic cystitis in a pediatric cohort. 60 In two separate studies Elmaagacli et al. 61, 62 investigated the TLR9 SNP rs187084. Initial results were promising in both retrospective and prospective cohorts where recipient homozygosity for the minor allele was associated with improved treatment related mortality, relapse incidence and overall survival. However in the multivariate analyses only an association with treatment related mortality remained significant. 61 Several other SNPs across most of the human TLR genes have been investigated in different settings of HSCT (Table 1) . Although associations between genotype and primarily aGvHD have been observed, the observations are from retrospective heterogenic transplant series, that as of yet have not been validated in independent cohorts. were significantly associated with invasive aspergillosis.
Bochud et al.
56
Case/control design with discovery (n = (Thr399Ile) and rs4986790 (Asp299Gly), was associated with invasive aspergillosis in the discovery cohort and in unrelated recipients in the validation cohort.
Koldehoff et al. (Thr399Ile) and/or rs4986790 (Asp299Gly) was associated with invasive aspergillosis.
de Boer et al.
58
Case/control, n =
108
Not available Not available 5 SNPs in TLR 2,4 and 6 Donor carriage of TLR4 rs4986790 (Asp299Gly) was associated with invasive aspergillosis.
Carvalho et al.
67
221
Myeloablative Matched related or haploidentical related (65%) 8 SNPs in TLR2, 4 and 9 In univariate analyses recipient carriage of the minor allele of TLR4 rs4986790 (Asp299Gly) or rs4986791 (Thr399Ile) was associated with increased incidence of mold colonization, and decreased incidence of invasive mold infection.
Lorenz et al.
52
237

Myeloablative
Matched related 2 SNPs in TLR4 Presence of the minor allele of any of the SNPs rs4986791 (Thr399Ile) and rs4986790 (Asp299Gly) in either donor or recipient was non-significantly associated with lower incidence of acute GVHD and higher risk of gram negative sepsis.
Mensah et al. No association between genotype (rs5744168) and blood stream infection was observed.
Gruhn et al. 2 SNP in TLR4 Recipient or donor carriage of the minor allele of rs4986790 (Asp299Gly) was associated with lower incidence of hemorrhagic cystitis. Similar trend was observed for rs4986791 (Thr399Ile).
Elmaagacli et al.
53
Case/control, n = In univariate analyses presence of the minor allele of rs4986791 (Thr399Ile) in recipients or both in donors and recipients was associated with increased incidence of severe GVHD. The finding were non-significant in the multivariate analysis.
Sivula et al.
69
Case/control, n = increased grade II-IV acute GVHD, and donor homozygosity for the minor allele of TLR9 (rs352140) was associated with increased incidence of CMV infection.
61
Case/control (n = 293) and a prospective cohort (n =
120)
Myeloablative Matched related or unrelated 2 SNPs in TLR 9 Recipient homozygosity for the rs187084 minor allele was significantly associated with reduced risk of treatment related mortality in the multivariate analyses.
62
142
Myeloablative and nonmyeloablative (4%)
Matched related 2 SNPs in TLR 9
Recipient homozygosity for the rs187084 minor allele was significantly associated with lower relapse incidence and superior overall survival in the univariate analyses, but not in the multivariate analyses.
Kornblit et al. 23 SNPs across all 10 TLRs. Donor hemizygosity or heterozygosity for the minor allele of TLR8 rs3764879 which is located on the X-chromosome were associated with overall survival in the multivariate models that were corrected for multiple comparisons.
In the associations column, the outcome parameter of interest is marked in bold.
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In the largest study to date of TLR SNPs in the setting of HSCT, 23 SNPs across 10 TLR genes were investigated in a cohort of 816 unrelated transplants reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). 55 The study included 12 previously investigated SNPs in TLR 1 (rs3923647, rs5743611 and rs5743618), 2 (rs1898830 and rs5743707), 3 (rs3775391), 4 (rs4986791 (Thr399Ile) and rs4986790 (Asp299Gly)), 5 (rs5744168), 6 (rs5743810) and 9 (rs187084 and rs5743836). None of the previously published associations between genotypes and outcome were confirmed in the multivariate models at the Bonferroni corrected level of P p 0.001. However, trends were observed for patient carriage of the TLR4 SNP rs4986790 minor allele, which was associated with TRM and OS at the P o 0.05 level, lending support to the probable importance of TLR4 genotype on infection related morbidity and mortality. Furthermore a novel statistically significant association between a TLR 8 promoter SNP in donors was associated with disease free survival.
Apart from TLR4, where several observations are suggestive of an association with invasive aspergillosis and possibly treatment related mortality, the body of available data on the associations between TLR genotypes and outcomes after allogeneic HSCT are inconsistent due to, in general, small and heterogeneous study cohorts. In spite of these obstacles it is probably still too early to entirely disregard the role of TLR genotypes in allogeneic HSCT, as the individual studies present data that are suggestive. However, before TLR genotyping can be used in clinical risk stratification, donor selection or personalized supportive care, further prospective studies in well-defined homogenous cohorts are needed.
Evidence from clinical trials investigating TLR-mediated immunomodulation of the allo-responses does not presently exist. Currently the only trial in allogeneic transplantation registered at ClinicalTrials.gov is NCT02452697. In this phase II trial transplant recipients are randomized between receiving natural killer cell enriched donor lymphocyte infusions alone or concomitantly with a TLR9 agonist with progression-free survival as an endpoint. A similar study in autologous transplantation is registered (NCT02115126), where patients with Epstein Bar Virus positive lymphomas are randomized to receive dendritic cell vaccines alone or concomitantly with a TLR9 agonist.
FUTURE PERSPECTIVES
Taken together there is an increasing body of evidence to suggest that PRR mediated sensing of both microbial -and endogenously derived molecular patterns influences the risk of an adverse outcome of HSCT. This evidence is, however, mainly based on studies in animals. Evidence from the clinical setting is mainly based on SNP association studies with findings that have to a large extent been inconsistent. Moreover, results obtained across the different species studied, and even within the same species, have to a large extent led to inconsistent results. Accordingly, much has still to be learned on the more definite roles of the TLRs in the clinical setting of HSCT.
Studies that include non-PRR mediated effects of the bacterial flora may lead to a better understanding of host-microbiome interactions in HSCT. A number of bacterial products (for example ATP and tryptophan metabolites) have been found to regulate the activation and expansion of Th17 cells and Tregs in the intestinal mucosa. Such mechanisms may play a role in tuning the immune system following HSCT, thereby influencing alloreactivity as well as protection against infections. 63 A field of particular interest is the possibility of modulating TLR signaling thereby reducing the risk of harmful systemic inflammation and aGvHD while preserving the beneficial GVT effect. In particular approaches to control host-microbiome interactions at the local level, in the gut or at sites of aGvHD, while sparing the sites of residual malignancy such as the hematopoietic tissues, could allow selective control of aGvHD. Such progress will require in-depth understanding of the molecular mechanisms in these interactions as well as large clinical studies in well-defined homogenous cohorts of patients.
